Welichem Biotech Inc. (“Welichem” or “the Company”) is a publicly traded company (Toronto Stock Venture Exchange, TSX-V: WBI) engaged in the discovery, development, and commercialization of pharmaceutical drugs, through its unique, patented SymbioChem® technology platform. More...

• Strong Pipeline – Discovery and development of two classes of drugs with distinctive disease targets:
  • WBI-1000 series for autoimmune/inflammatory diseases, psoriasis
  • WBI-2000 series for cancer
• Huge Market Potential – Targeted markets exceed $ US 70 billion annually
• Extensive IP Protection – Ten patents worldwide with 29 additional patent applications pending
• Advantageous Position – Phase I and Phase IIa Clinical Trial completed for the topical treatment of Psoriasis and Topical Dermatitis (Eczema), respectively. Pre-clinical trials in progress for cancer treatment and reduction of potentially fatal side effects of chemotherapy
• Attractive Acquisition or Joint Venture Candidate – Welichem’s synergistic patented small molecule drug candidates should attract major pharmaceutical companies needing to increase their new drug pipelines by licensing or acquisition